Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

The likelihood for obstructive sleep apnea went down by 74% among adults with optimal vs. insufficient healthy lifestyle ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Women with pregnancy-onset OSA had significantly higher nocturnal systolic BP and daytime diastolic BP, relative to those ...

By Adeola Adebisi Thaddeus Atta, fondly known for his slogan “Smile Joor”, has been a beacon of hope and transformation in Eti-Osa Federal Constituency, Lagos State. Since assuming office, he has ...

Short-term HRV is significantly associated with poor daytime psychomotor vigilance performance among both men and women with ...

At CES 2025, Laptop Mag was spoilt for choice when it came to picking Laptop Laurels winners, but when a keyboard like the ...

Mineralys Therapeutics (MLYS) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...

Adults with obstructive sleep apnea (OSA) are at increased risk for vertigo and vestibular dysfunction, relative to those without OSA.

Not every football season can be a masterpiece, but even in the chaos, there are moments worth celebrating. The Dallas ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.